Wellington Management Group Portfolio holdings
Wellington Management Group, founded in 1928 by Walter L. Morgan and headquartered in Boston, Massachusetts, is one of the world’s largest independent asset management firms, overseeing trillions in assets for a diverse client base including pension funds, endowments, and mutual fund investors. Renowned for its active management approach, Wellington offers a broad range of investment strategies across equities, fixed income, multi-asset, and alternative investments, emphasizing deep research and long-term partnerships with clients. The firm gained early fame for launching the Wellington Fund, one of the first balanced mutual funds, and has since maintained a reputation for disciplined, collaborative portfolio management. With a global presence and a focus on customized solutions, Wellington remains a trusted name in institutional and retail investing.
Top Buys
| 1 |
Broadcom
AVGO
|
+$2.09B |
| 2 |
Mastercard
MA
|
+$2.06B |
| 3 |
UnitedHealth
UNH
|
+$1.3B |
| 4 |
Coca-Cola
KO
|
+$1.17B |
| 5 |
Marsh & McLennan
MMC
|
+$1.1B |
Top Sells
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$1.55B |
| 2 |
Apple
AAPL
|
+$1.51B |
| 3 |
JPMorgan Chase
JPM
|
+$1.34B |
| 4 |
General Dynamics
GD
|
+$1.25B |
| 5 |
Wells Fargo
WFC
|
+$1.17B |
Sector Composition
| 1 | Technology | 21.49% |
| 2 | Healthcare | 18.42% |
| 3 | Financials | 15.97% |
| 4 | Consumer Discretionary | 9.49% |
| 5 | Industrials | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1551
Theravance Biopharma
TBPH
$689M
| $1.39M | ﹤0.01% |
155,429
-43,062
| -22% | -$385K |
|
1552
NET Power
NPWR
$167M
| $1.35M | ﹤0.01% |
512,889
-179,300
| -26% | -$472K |
|
|
SWTX
1553
DELISTED
SpringWorks Therapeutics
SWTX
| $1.35M | ﹤0.01% |
30,563
-618
| -2% | -$27.3K |
|
1554
Phibro Animal Health
PAHC
$1.65B
| $1.35M | ﹤0.01% |
63,113
-18,885
| -23% | -$403K |
|
1555
Avantor
AVTR
$8.82B
| $1.34M | ﹤0.01% |
82,392
-839,766
| -91% | -$13.6M |
|
1556
Unitil
UTL
$808M
| $1.33M | ﹤0.01% |
23,105
| – | – |
|
1557
Target
TGT
$41.2B
| $1.33M | ﹤0.01% |
12,759
-43,625
| -77% | -$4.55M |
|
1558
Gildan
GIL
$8.18B
| $1.33M | ﹤0.01% |
30,042
+2,285
| +8% | +$101K |
|
1559
Orrstown Financial Services
ORRF
$679M
| $1.32M | ﹤0.01% |
44,119
-1,069
| -2% | -$32.1K |
|
1560
MindMed
MNMD
$738M
| $1.32M | ﹤0.01% |
225,928
+31,437
| +16% | +$184K |
|
1561
Akebia Therapeutics
AKBA
$793M
| $1.28M | ﹤0.01% |
666,567
+164,440
| +33% | +$316K |
|
1562
Restaurant Brands International
QSR
$20.3B
| $1.28M | ﹤0.01% |
19,185
+2,250
| +13% | +$150K |
|
1563
DaVita
DVA
$9.81B
| $1.28M | ﹤0.01% |
8,348
+5,637
| +208% | +$862K |
|
1564
CubeSmart
CUBE
$9.28B
| $1.27M | ﹤0.01% |
29,725
-780,108
| -96% | -$33.3M |
|
1565
Howmet Aerospace
HWM
$72B
| $1.26M | ﹤0.01% |
9,751
-65
| -0.7% | -$8.43K |
|
1566
EyePoint Pharmaceuticals
EYPT
$975M
| $1.26M | ﹤0.01% |
233,231
+55,915
| +32% | +$303K |
|
1567
Phathom Pharmaceuticals
PHAT
$896M
| $1.26M | ﹤0.01% |
200,690
+64,695
| +48% | +$406K |
|
1568
MoonLake Immunotherapeutics
MLTX
$3.68B
| $1.26M | ﹤0.01% |
32,163
-66,935
| -68% | -$2.62M |
|
1569
Zebra Technologies
ZBRA
$15.8B
| $1.25M | ﹤0.01% |
4,440
-6,705
| -60% | -$1.89M |
|
1570
Rhythm Pharmaceuticals
RYTM
$6.66B
| $1.25M | ﹤0.01% |
23,558
-1,997
| -8% | -$106K |
|
1571
Toast
TOST
$23.9B
| $1.24M | ﹤0.01% |
37,469
+18,971
| +103% | +$629K |
|
1572
Chemed
CHE
$6.75B
| $1.24M | ﹤0.01% |
2,014
-230
| -10% | -$142K |
|
1573
Dianthus Therapeutics
DNTH
$1.11B
| $1.23M | ﹤0.01% |
67,982
+7,645
| +13% | +$139K |
|
1574
Vanda Pharmaceuticals
VNDA
$265M
| $1.22M | ﹤0.01% |
265,888
-82,958
| -24% | -$381K |
|
1575
Cullinan Oncology
CGEM
$411M
| $1.22M | ﹤0.01% |
161,057
+28,081
| +21% | +$213K |
|